» Articles » PMID: 27987537

Comparison of Hepatic MDCT, MRI, and DSA to Explant Pathology for the Detection and Treatment Planning of Hepatocellular Carcinoma

Overview
Specialty Gastroenterology
Date 2016 Dec 19
PMID 27987537
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: The diagnosis and treatment plan for hepatocellular carcinoma (HCC) can be made from radiologic imaging. However, lesion detection may vary depending on the imaging modality. This study aims to evaluate the sensitivities of hepatic multidetector computed tomography (MDCT), magnetic resonance imaging (MRI), and digital subtraction angiography (DSA) in the detection of HCC and the consequent management impact on potential liver transplant patients.

Methods: One hundred and sixteen HCC lesions were analyzed in 41 patients who received an orthotopic liver transplant (OLT). All of the patients underwent pretransplantation hepatic DSA, MDCT, and/or MRI. The imaging results were independently reviewed retrospectively in a blinded fashion by two interventional and two abdominal radiologists. The liver explant pathology was used as the gold standard for assessing each imaging modality.

Results: The sensitivity for overall HCC detection was higher for cross-sectional imaging using MRI (51.5%, 95% confidence interval [CI]=36.2-58.4%) and MDCT (49.8%, 95% CI=43.7-55.9%) than for DSA (41.7%, 95% CI=36.2-47.3%) (=0.05). The difference in false-positive rate was not statistically significant between MRI (22%), MDCT (29%), and DSA (29%) (=0.67). The sensitivity was significantly higher for detecting right lobe lesions than left lobe lesions for all modalities (MRI: 56.1% vs. 43.1%, MDCT: 55.0% vs. 42.0%, and DSA: 46.9% vs. 33.9%; all <0.01). The sensitivities of the three imaging modalities were also higher for lesions ≥2 cm vs. <2 cm (MRI: 73.4% vs. 32.7%, MDCT: 66.9% vs. 33.8%, and DSA: 62.2% vs. 24.1%; all <0.01). The interobserver correlation was rated as very good to excellent.

Conclusion: The sensitivity for detecting HCC is higher for MRI and MDCT than for DSA, and so cross-sectional imaging modalities should be used to evaluate OLT candidacy.

Citing Articles

Feeding artery characteristics and enhancement patterns of hepatoblastoma patients treated with transarterial chemoembolization (TACE): Digital subtraction angiography evaluation.

Yus T, Sarastika H, Soeprijanto B Narra J. 2024; 3(3):e209.

PMID: 38455610 PMC: 10919712. DOI: 10.52225/narra.v3i3.209.


Efficacy Evaluation on the Color Doppler Ultrasound, Multislice Spiral CT Combined with Serum Markers in Diagnosis of Primary Hepatic Carcinoma.

Zhao X, Xia Y, Li C, Wang D Iran J Public Health. 2021; 50(8):1603-1612.

PMID: 34917531 PMC: 8643511. DOI: 10.18502/ijph.v50i8.6806.


Glypican-3 targeted delivery of Zr and Y as a theranostic radionuclide platform for hepatocellular carcinoma.

Labadie K, Ludwig A, Lehnert A, Hamlin D, Kenoyer A, Sullivan K Sci Rep. 2021; 11(1):3731.

PMID: 33580090 PMC: 7881163. DOI: 10.1038/s41598-021-82172-w.


Multiphase convolutional dense network for the classification of focal liver lesions on dynamic contrast-enhanced computed tomography.

Cao S, Zhang L, Kuang S, Shi W, Hu B, Xie S World J Gastroenterol. 2020; 26(25):3660-3672.

PMID: 32742134 PMC: 7366064. DOI: 10.3748/wjg.v26.i25.3660.

References
1.
Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View

2.
Gallix B, Reinhold C, Dauzat M, Bret P . Streamlined flow in the portal vein: demonstration with MR angiography. J Magn Reson Imaging. 2002; 15(5):603-9. DOI: 10.1002/jmri.10108. View

3.
Bartolozzi C, Lencioni R, Caramella D, Palla A, Bassi A, Di Candio G . Small hepatocellular carcinoma. Detection with US, CT, MR imaging, DSA, and Lipiodol-CT. Acta Radiol. 1996; 37(1):69-74. DOI: 10.1177/02841851960371P114. View

4.
Saar B, Kellner-Weldon F . Radiological diagnosis of hepatocellular carcinoma. Liver Int. 2008; 28(2):189-99. DOI: 10.1111/j.1478-3231.2007.01655.x. View

5.
Tanwar S, Khan S, Grover V, Gwilt C, Smith B, Brown A . Liver transplantation for hepatocellular carcinoma. World J Gastroenterol. 2009; 15(44):5511-6. PMC: 2785052. DOI: 10.3748/wjg.15.5511. View